logo-loader

Genprex launches new branding for its lead drug REQORSA in preparation for upcoming studies

Published: 10:28 06 Nov 2020 EST

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based group has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrissoib and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC).

Varner says these trials will use the brand name, “Acclaim,” which the company believes evokes the enthusiasm and hope these trials represent for NSCLC patients and the oncology community. Acclaim-1 will refer to the Tagrisso combination clinical trial, and Acclaim-2 will refer to the Keytruda combination clinical trial.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

23 minutes ago